Form 8-K · Current Report · Filed 2024-05-02
Cardinal Health Reports Third Quarter FY24 Results and Raises Guidance
Cardinal Health, Inc. reported a 9% increase in revenues for the third quarter of fiscal year 2024, reaching $54.9 billion, driven by growth in both the Pharmaceutical and Specialty Solutions segment and the Global Medical Products and Distribution segment. The company's non-GAAP diluted earnings per share increased by 20% to $2.08. Cardinal Health also raised its fiscal year 2024 non-GAAP EPS guidance to a range of $7.30 to $7.40 and provided preliminary guidance for fiscal year 2025 at least $7.50.
- Filer
- Cardinal Health Inc. CAH · NYSE
- Filed
- Accession
- 0000721371-24-000036
- CIK
- 0000721371
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$102.17
Next session
-3.2%
Since filing
+125.1%
Latest close
$230.03
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CAH reporting the same item, with the next session's move:
Exhibits (1)
About Cardinal Health Inc.
Cardinal Health Inc. is a major global healthcare services and products company, distinguished for providing end-to-end medical solutions. Specializing in healthcare distribution and supply chain management, Cardinal Health serves a comprehensive array of clients including hospitals, pharmacies, and healthcare providers. Notably, the company distributes pharmaceuticals, medical products, and laboratory supplies, ensuring efficient delivery to improve healthcare outcomes. Based in Dublin, Ohio, Cardinal Health plays a pivotal role in enhancing healthcare operational efficiency, offering extensive services like inventory management, logistics optimization, and integrated healthcare solutions that empower providers to focus on patient care. As one of the largest pharmaceutical distributors in the United States, it holds substantial influence in the healthcare sector, pivotal in ensuring the availability of drugs and medical supplies across various platforms, contributing significantly to the healthcare infrastructure worldwide.
Never miss another CAH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.